FDA approves first new tuberculosis in 40 years

The Food and Drug Administration says it has approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

The agency approved J&J's pill, Sirturo, for use with other older drugs to fight hard-to-treat .

Sirturo is the first medicine specifically designed for treating multi-drug-resistant tuberculosis. That's an increasingly common form of the disease that cannot be treated with at least two of the four primary antibiotics used to treat tuberculosis.

The standard drugs used to fight the disease were developed in the 1950s and 1960s.

Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drug-resistant TB blamed on Indian treatment flaws

Mar 23, 2012

(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Recommended for you

Discount generic drug programs grow over time

4 hours ago

Generic discount drug programs (GDDPs, which charge nominal fees to fill prescriptions) have grown over time and their initial lower use by racial/ethnic minorities has evaporated, writes author Song Hee Hong, Ph.D., of the ...

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

tekram
not rated yet Dec 31, 2012
This looks similar to a quinolone drug such as cipro, but it is not. Discovered by Koen Andries and his team at Janssen Pharmaceutica, Bedaquiline was described for the first time in 2004.
Bedaquiline affects the proton pump for ATP synthase, which is unlike the quinolones, whose target is DNA gyrase.